Literature DB >> 11407999

Serum cystatin C in patients with myeloma.

H Finney1, A H Williams, C P Price.   

Abstract

BACKGROUND: Cystatin C is a low molecular weight protein thought to be synthesised by all nucleated cells and freely filtered by the kidney. It has been proposed as a marker for GFR; however, it has been suggested that there may be limitations to its use, because it may be over-expressed in some tumour cells and the abnormal tissue growth may also lead to an increased circulating level.
METHODS: We investigated the serum cystatin C levels in 60 patients with myeloma, comparing results with those for serum creatinine, beta(2)-microglobulin and the paraprotein concentration.
RESULTS: We found no correlation between cystatin C and the paraprotein concentration in these patients.
CONCLUSION: These results suggest that disease burden does not correlate to the circulating level of cystatin C in patients with myeloma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407999     DOI: 10.1016/s0009-8981(01)00415-6

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  9 in total

Review 1.  Commentary: clinical diagnostic use of cystatin C.

Authors:  Davis Massey
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

2.  Cystatin C-based equation for estimating glomerular filtration rate in Japanese children and adolescents.

Authors:  Osamu Uemura; Takuhito Nagai; Kenji Ishikura; Shuichi Ito; Hiroshi Hataya; Yoshimitsu Gotoh; Naoya Fujita; Yuko Akioka; Tetsuji Kaneko; Masataka Honda
Journal:  Clin Exp Nephrol       Date:  2013-11-20       Impact factor: 2.801

3.  Reference serum cystatin C levels in Japanese children.

Authors:  Osamu Uemura; Katsumi Ushijima; Takuhito Nagai; Takuji Yamada; Hideki Hayakawa; Yayoi Nabeta; Yoshiko Shinkai; Kouichi Koike; Masaki Kuwabara
Journal:  Clin Exp Nephrol       Date:  2010-07-06       Impact factor: 2.801

4.  The role of cystatin C and the angiogenic cytokines VEGF and bFGF in patients with esophageal carcinoma.

Authors:  Martin Dreilich; Gunnar Wagenius; Stefan Bergström; Daniel Brattström; Anders Larsson; Patrik Hesselius; Michael Bergqvist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

5.  Cystatin C--a paradigm of evidence based laboratory medicine.

Authors:  Janice S C Chew; Mohammed Saleem; Christopher M Florkowski; Peter M George
Journal:  Clin Biochem Rev       Date:  2008-05

6.  Comparison of glomerular function tests in children with cancer.

Authors:  Marika H Grönroos; Timo Jahnukainen; Kerttu Irjala; Risto Härkönen; Saija Hurme; Merja Möttönen; Toivo T Salmi
Journal:  Pediatr Nephrol       Date:  2008-01-23       Impact factor: 3.714

7.  Serum levels of cystatin C in patients with malignancy.

Authors:  Keiko Nakai; Masayuki Kikuchi; Keiko Fujimoto; Yoshito Kaneko; So Omori; Kenji Nakai; Akira Suwabe
Journal:  Clin Exp Nephrol       Date:  2008-03-05       Impact factor: 2.801

8.  Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.

Authors:  Evangelos Terpos; Eirini Katodritou; Evangelos Tsiftsakis; Efstathios Kastritis; Dimitrios Christoulas; Anastasia Pouli; Eurydiki Michalis; Evgenia Verrou; Konstantinos Anargyrou; Konstantinos Tsionos; Meletios A Dimopoulos; Konstantinos Zervas
Journal:  Haematologica       Date:  2009-03       Impact factor: 9.941

9.  Factors other than the glomerular filtration rate that determine the serum beta-2-microglobulin level.

Authors:  Zeno Stanga; Stefan Nock; Pedro Medina-Escobar; Urs E Nydegger; Martin Risch; Lorenz Risch
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.